source
- Summit and Akeso's ivonescimab beats Merck's Keytruda in Chinese NSCLC trialSummit Therapeutics and Akeso reported that their bispecific PD-1/VEGF antibody ivonescimab outperformed Merck's Keytruda in a Phase 3 HARMONi-2 trial conducted in China. The study enrolled first‑l…
- BioNTech stops Phase 2 colorectal cancer mRNA vaccine trial after futility findingsBioNTech announced that it is ending its Phase 2 study of a personalized mRNA vaccine for resected colorectal cancer after the trial failed to show the needed benefit. The news sent the company’s s…